29 September 2023
29 September 2023
The small-cap segment is heavily populated by Chinese companies, following just behind US businesses.
The FDA has approved the therapy based on data from the Phase III PROPEL pivotal study.
HitGen will leverage its DEL technology platform for screening under-represented targets selected by SGC.
As part of the latest investment, MPM-BioImpact’s Detlev Biniszkiewicz will join the board of Deka.
Exxua, which was studied in more than 5,000 patients, demonstrated an overall acceptable safety profile.
Bosutinib has been approved for adults for ten years, but the FDA has secured approval for use in children.
The company’s algorithms put proteins through millions of years of simulated evolution to identify potential functional candidates.
Currently, eight states in the US demand that health insurance plans cover OTC contraceptives.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.
